PROGNOSIS IN PATIENTS WITH CHRONIC HEART FAILURE: THE ROLE OF ENALAPRIL
- Authors: Strizhakov L.1
-
Affiliations:
- I.M. Sechenov First Moscow State Medical University
- Issue: Vol 23, No 5 (2012)
- Pages: 57-60
- Section: Articles
- URL: https://journals.eco-vector.com/0236-3054/article/view/115475
- ID: 115475
Cite item
Open Access
Access granted
Abstract
The paper discusses the experience of clinical trials of enalapril used in patients with chronic heart failure.
Full Text
About the authors
L. Strizhakov
I.M. Sechenov First Moscow State Medical University
Email: strizhakov76@mail.ru
Candidate of Medical Sciences
References
- Mancia G. Blood pressure variability: mechanisms and clinical significance // J. Cardiovasc. Pharmacol. - 1990; 16: 1-6.
- Pfeffer M., Pfeffer I. Reversing cardiac hypertrophy in hypertension // N. Engl. J. Med. - 1990; 322: 1388-90.
- Vakili B., Okin P., Devereux R. Prognostic implications of left ventricular hypertrophy // Am. Heart. J. - 2001; 141: 334-41.
- Беленков Ю.Н., Мареев В.Ю., Агеев Ф.Т. Хроническая сердечная недостаточность: избранные лекции по кардиологии / М.: ГЭОТАР-Медиа, 2006; 428 с.
- Терещенко С.Н. Систолическая функция левого желудочка в развитии хронической сердечной недостаточности и ингибиторы АПФ // Consilium Medicum. - 2002; 4 (11): 32-5.
- Мазур Н.А. Систолическая форма хронической застойной сердечной недостаточности и ее лечение // Тер. арх. - 1996; 8: 5-8.
- Lob H., Rosenkranz A., Breitenbach T. et al. Antioxidant and Nitric Oxide Sparing Actions of Dihydropyridines and ACE Inhibitors Differ in Human Endothelial Cells // Pharmacology. - 2005; 76 (1): 8-18.
- Yoshida H., Kusama Y., Kodani E. et al. Pharmacological Preconditioning With Bradykinin Affords Myocardial Protection Through NO-dependent Mechanisms // Int. Heart. J. - 2005; 46 (5): 877-87.
- Goldsmith S. Interactions between the sympathetic nervous system and the RAAS in heart failure // Curr. Heart. Fail. Rep. - 2004; 1 (2): 45-50.
- Demers C., Mody A., Teo K. et al. ACE Inhibitors in Heart Failure: What More Do We Need to Know? // Am. J. Cardiovasc. Drugs. - 2005; 5 (6): 351-9.
- Sharpe D., Murphy J., Coxon R. et al. Enalapril in patients with chronic heart failure: a placebo-controlled, randomized, double-blind study // Circulation. - 1984; 70: 271-8.
- The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS) // N. Engl. J. Med. - 1987; 316: 1429-35.
- The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions // N. Engl. J. Med. - 1992; 327: 685-91.
- Johnson G., Carson P., Francis G., Cohn J. Influence of prerandomization (baseline) variables on mortality and on the reduction of mortality by enalapril. Veterans Affairs Cooperative Study on Vasodilator Therapy of Heart Failure (V-HeFT II). V-HeFT VA Cooperative Studies Group // Circulation. - 1993; 87 (6): 132-9.
- Vermes E., Ducharme A., Bourassa M. et al. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) // Circulation. - 2003; 107 (9): 1291-6.
- Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (3-й пересмотр) // Сердечная недостаточность. - 2010; 11 (1): 57.
- Стуров Н.В. Применение эналаприла при артериальной гипертензии и хронической сердечной недостаточности: патофизиологическое обоснование и доказательная база. Трудный пациент. 2011; 9: 5: 13-16.
- Andrejak M., Zannad F., Laville M. Evalution of different approaches t o the treatment of arterial hypertension: combination treatment with low dose perindopril / indapamid versus sequential treatment of stepped-dose treatment. // Therapie 2003; 58(4):351-52
- Фомин В.В. Долгосрочное управление риском при артериальной гипертензии: фокус на периндоприл. // Фарматека. - 2011; 8 (221): 8-13.
Supplementary files
